Obesity is a risk factor for endothelial dysfunction and hypertension in pregnancy. Our lab has demonstrated that obesity-associated hypertension in female animal models develops via leptin-mediated, aldosterone-induced endothelial dysfunction (ED). We also showed that female mice are more sensitive to leptin-induced aldosterone activation of endothelial mineralocorticoid receptors (ECMR) due to an endogenous sex-specific upregulation of ECMR in females. Our previous data demonstrates that endothelial progesterone receptor activation increases ECMR expression and that ECMR deletion protects female mice from obesity-associated, leptin-mediated ED. However, whether ECMR play a role in ED in pregnancy is unknown. Therefore, we hypothesized that high progesterone levels increase ECMR expression in pregnant mice and that ECMR deletion protects pregnant mice from obesity-associated, leptin-mediated ED. Endothelial cells were isolated from aorta of timed-pregnant Balb/C mice (gestation day (GD) 17) and assessed for ECMR expression via RT-PCR. ECMR mRNA expression increased 9.2±0.2-fold (*P<0.05) in pregnant compared to nonpregnant mice in association with high plasma progesterone levels (24±6 ng/ml pregnant vs 2±2 nonpregnant, *P<0.05). Endothelial function was experimentally measured by wire myography concentration response curves to acetylcholine in mouse aorta analyzed by 2-way ANOVA of curves with repeated measures. No changes in endothelial-independent sodium nitroprusside responses were observed. Chronic leptin infusion in mid-pregnancy (GD11-17) induced ED in pregnant mice that was impaired both compared to sham-treated pregnant (*P<0.05) and non-pregnant leptin-infused females (*P<0.05), indicating that increased ECMR expression in pregnancy increases sensitivity to leptin-induced ED. Further evidence for this notion is provided in that ECMR deletion in pregnant mice protected them from leptin-mediated ED (*P<0.05). Collectively, these data indicate a role for ECMR in the pathogenesis of obesity-associated ED in pregnancy and indicate a potential role for MR antagonists for the treatment of hypertensive pregnancies such as preeclampsia.